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Introduction
Cowden’s Syndrome (CS) is an autosomal dominant, 
hereditary, and multisystem disease resulting in multiple 
hamartomas throughout the body with an increased risk 
of several carcinomas (1,2). It has incomplete penetrance 
and variable expressivity with a germline mutation in 
the phosphatase and tensin homolog (PTEN) tumor 
suppressor gene on chromosome 10q23.3 (3,4). CS causes 
an increased risk of breast, thyroid, endometrial, and renal 
cell cancers with lifetime risk as high as 85%, 35%, 28%, 
and 35%, respectively (5,6). Increased rate and number 
of meningiomas in CS has been described in case reports. 
However meningiomas do not fall under the syndrome’s 
diagnostic criteria due to lack of data and high prevalence 
in the general population (7,8). CS is rare with an estimated 
prevalence of 1:200,000 patients; but this figure is likely an 
underestimation due to under diagnosis (9).
There is a lack of evidence describing the effects of 
radiation as a treatment modality in this patient population. 
Experimental studies have shown radiation sensitivity 
following PTEN inhibition in cell lines (10). Limited case 
reports have also described the negative effects of treating 
CS patients with radiation therapy (RT) including secondary 
malignancies, radiation dermatitis, and neurotoxicity 
(10,11). Patients with CS and unresectable meningiomas 
pose a conundrum: is RT safe in this population? We 
present the following case of a 35-year-old woman with CS 
and multiple meningiomas treated with multiple bouts of 
RT in accordance with the CARE-Guideline (12).
Case presentation
A 35-year-old woman presented to our institution with a 
recent diagnosis of CS and a magnetic resonance imaging 
(MRI) of the brain was performed as part of her evaluation. 
MRI demonstrated a lesion in the cerebellum suggesting 
dysplastic gangliocytoma consistent with Lhermitte-
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Duclos disease (LDD), considered part of CS, as well as 
five intracranial, homogeneously enhancing masses of the 
meninges consistent with meningiomas. The meningeal 
lesions were left frontal parafalcine, left frontal convexity, 
left paraclinoid, right petroclival, and right olfactory groove, 
measuring 3.9, 3.4, 2.2, 3.3, and 0.4 cm in the longest 
dimension, respectively (Figure 1). There was 1.6 cm 
of brainstem compression in the region of the pons from 
the petroclival lesion, and optic nerve abutment from the 
paraclinoid mass. She was otherwise asymptomatic, and her 
neurological exam was normal.
First treatment
The pat ient  underwent a  r ight  middle fossa  and 
retrosigmoid craniotomy for resection of the right 
petroclival meningioma. Subtotal resection (Simpson grade 
IV) was achieved due to the fibrous nature of the lesion 
and risk of cranial neuropathy. Pathology revealed low-
grade spindle cell processes, Ki-67 <1%, with positive 
immunohistochemical stains for EMA and vimentin, 
consistent with World Health Organization (WHO) grade 
I meningioma. Post-operative MRI of the brain showed 
surgical changes with significant residual petroclival 
disease and stability of the remaining meningiomas. Her 
recovery was complicated by mild right sixth nerve palsy 
and hoarseness which improved with follow-up. She was 
referred to radiation oncology, and adjuvant RT was 
recommended to the residual disease. Active surveillance 
was elected for the remaining lesions as they were 
asymptomatic, the patient did not want surgery, and concern 
for malignant transformation from RT in the setting of CS. 
The patient underwent fractionated stereotactic radiation 
therapy (FSRT) 50 Gy in 25 fractions with a 2 mm 
margin, prescribed to the 97% isodose line, using four 
arcs and five modulated static beams (Figure 2). Mean dose 
to the brainstem was 21.8 Gy, with maximal point dose 
of 51.7 Gy. She completed adjuvant therapy four months 
postoperatively with only grade 1 fatigue, headaches, and 
nausea that self-resolved.
Follow-up brain MRI six months post adjuvant RT 
showed interval decrease in the size of the right petroclival 
meningioma from 2.4×3.0 to 1.9×1.8 cm2 with decreased 
mass effect on the brainstem, and no evidence of brainstem 
A B
C D
Figure 1 Initial preoperative magnetic resonance imaging. Preoperative MRI of the brain T1 weighted post-gadolinium sequence with 
representative axial planes of the left paraclinoid (A), left parafalcine and convexity (B), right petroclival with compression of the pons (C), 
and right olfactory groove (D) meningiomas.
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edema. There was interval progression of the left frontal 
parafalcine meningioma from 3.7×2.4 to 3.8×2.6 cm2 and 
stability of the remaining three lesions. She continued to 
be asymptomatic with no visual deficits. Surgical resection 
was recommended due to progression. However, the patient 
elected for continued surveillance.
Second treatment
At 18 months post-operatively the patient presented with 
new onset of mild right arm weakness and headaches. MRI 
at this time revealed progression of left parafalcine and 
left frontal convexity meningiomas, significantly increased 
cerebral edema, and increased mass effect with abutment of 
the sagittal sinus. Surgical intervention for these two lesions, 
the left clinoid, and right olfactory groove meningiomas was 
recommended but was delayed due to patient preference.
Two months later the patient underwent image-guided 
left frontotemporal craniotomy and achieved gross total 
resection (Simpson Grade II) for all sites of disease. Post-
operative MRI confirmed these changes as well as new small 
meningiomas in the right anterior cranial fossa and left 
tentorium, 3 and 5 mm respectively. Pathology of the left 
frontal specimen was WHO grade II atypical meningioma 
with brain invasion, reactive gliosis, and bone invasion with 
KI67 of 2%, and the remaining lesions were WHO grade I. 
The patient recovered without complication. 
M R I  o f  t h e  b r a i n  f i v e  m o n t h s  a f t e r  s u r g e r y 
demonstrated improvement in postoperative changes, 
enlargement of the left tentorial meningioma, and 
increased enhancement over the left frontal convexity 
thought to be due to surgical changes. The patient 
complained of occasional forgetfulness and fatigue but 
was otherwise doing well. Review of prior radiation plan 
did not reveal field overlap with new meningiomas, and 
definitive RT was recommended to the progressing lesion. 
She underwent stereotactic radiosurgery (SRS) to 15 Gy 
using four stereodynamic arcs prescribed to the 81% 
isodose line without margin, and minimal dose to critical 
structures (Figure 3). Neurosurgery reported thorough 
resection of the left frontal WHO grade II meningioma, 
therefore observation was elected. The patient tolerated 
treatment well and is currently being followed with 
ongoing surveillance. Most recent MRI showed no 
significant changes 32 months from original FSRT and 
7 months post-SRS. She has reported no long term side 
effects or toxicity as a result of her radiation treatments. 
A timeline of care received by the patient is available in 
Figure 4.
Discussion
There are few publications describing the use of 
RT in patients with CS. One case report (abstract) 
A B
Figure 2 Fractionated stereotactic radiotherapy plan. Radiation planning MRI of debulked right petroclival meningioma with representative 
axial (A) and sagittal (B) slices. Prescription dose was 50 Gy in 2 Gy fractions to the 97% isodose line. Isodose lines represent 20, 30, 40, and 
50 Gy doses, respectively.
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describes the discontinuation of adjuvant radiation to 
the breast due to severe skin desquamation (10). This 
same patient experienced near total hair loss in the first 
week of whole brain radiotherapy (WBRT) despite 
the use of hippocampal sparing, intensity modulated 
radiotherapy technique with the scalp receiving <10 Gy. 
Four months after completing WBRT the patient developed 
emesis, ataxia, and headache with MRI showing increased 
intracranial edema and nodular enhancement believed to be 
treatment-induced changes (10). In another report, a patient 
with CS was diagnosed with undifferentiated pleomorphic 
sarcoma (UPS) of the breast, thought to be from adjuvant 
RT for breast cancer seven years prior (11).
Our patient underwent multiple bouts of high dose, 
definitive RT. However, unlike the case report by Tatebe et 
al. our patient developed minimal toxicity or post-RT MRI 
changes (10). There are several potential explanations for 
the difference in outcomes. Firstly, we utilized stereotactic 
techniques with minimal margins. Given the potential for 
increased toxicity in this patient group, maximizing the 
Figure 3 Stereotactic radiosurgery plan. Radiation planning MRI of left tentorial meningioma with representative axial (A) and sagittal (B) 
slices. Prescription dose was 15 Gy, single fraction to the 81% isodose line. Isodose lines represent 2, 5, 10, and 15 Gy doses, respectively.
Figure 4 Timeline of Treatments. Timeline of care received by the patient including relevant radiographic imaging, surgeries, and 
radiotherapies. MRI, magnetic resonance imaging; STR, subtotal resection; FSRT, fractionated stereotactic radiotherapy; GTR, gross total 
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therapeutic ratio is critical, reinforcing the principle of 
“as low as reasonably achievable” (ALARA). The various 
levels of penetrance and expressivity inherent to CS may 
also provide explanation, with some patients possibly being 
more sensitive to RT than others. In the case report by 
Chandhanayingyong et al. they described the treatment 
of a patient with CS and Ewing sarcoma of the pelvis. 
The patient underwent neoadjuvant RT to 45 Gy prior to 
hemipelvectomy with no significant toxicity reported (13). 
There is no reliable way to identify patients that will develop 
significant treatment toxicity. Indeed, given that our patient 
had brain parenchymal manifestation of her disease via LDD, 
it would have been reasonable to presume increased risk of 
toxicity. Ultimately, the risk and benefits of RT should always 
be considered and catered to each patient individually.
Due to limited evidence and few reports describing 
these negative effects, RT has frequently been avoided in 
CS patients. The reluctance to use radiation in CS patients 
with intracranial disease leaves providers with limited 
therapeutic options. When treating CS patients, non-RT 
methods should be exhausted. If RT is necessary, highly 
conformal, stereotactic techniques with minimal dose to 
normal structures should be utilized to decrease potential 
toxicity. Our case demonstrates the first successful use of 
intracranial stereotactic RT in a CS patient. While more 
evidence is needed, this offers a potential treatment option 
for this patient population. 
In conclusion, we report the first case, to the best of our 
knowledge, of intracranial RT using stereotactic techniques 
in a patient with CS who has not demonstrated significant 
treatment toxicity to date. Previous reports of toxicity 
may be due to the variable penetrance of the CS and large 
RT fields used in prior reports. While RT has historically 
been avoided in CS patients due to concern for secondary 
malignancies and increased toxicity, consideration in select 
patients utilizing stereotactic techniques may be viable after 
exhaustion of non-RT interventions.
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